Correlation Between Supernus Pharmaceuticals and Oric Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Supernus Pharmaceuticals and Oric Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Supernus Pharmaceuticals and Oric Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Supernus Pharmaceuticals and Oric Pharmaceuticals, you can compare the effects of market volatilities on Supernus Pharmaceuticals and Oric Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Supernus Pharmaceuticals with a short position of Oric Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Supernus Pharmaceuticals and Oric Pharmaceuticals.

Diversification Opportunities for Supernus Pharmaceuticals and Oric Pharmaceuticals

-0.15

Correlation Coefficient

Supernus Pharmaceuticals  Oric Pharmaceuticals

Good diversification

The 3 months correlation between Supernus and Oric is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Supernus Pharmaceuticals and Oric Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oric Pharmaceuticals and Supernus Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Supernus Pharmaceuticals are associated (or correlated) with Oric Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oric Pharmaceuticals has no effect on the direction of Supernus Pharmaceuticals i.e., Supernus Pharmaceuticals and Oric Pharmaceuticals go up and down completely randomly.

Pair Corralation between Supernus Pharmaceuticals and Oric Pharmaceuticals

Given the investment horizon of 90 days Supernus Pharmaceuticals is expected to generate 9.98 times less return on investment than Oric Pharmaceuticals. But when comparing it to its historical volatility, Supernus Pharmaceuticals is 2.07 times less risky than Oric Pharmaceuticals. It trades about 0.01 of its potential returns per unit of risk. Oric Pharmaceuticals is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  560.00  in Oric Pharmaceuticals on September 29, 2024 and sell it today you would earn a total of  265.00  from holding Oric Pharmaceuticals or generate 47.32% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Supernus Pharmaceuticals  vs.  Oric Pharmaceuticals

Supernus Pharmaceuticals

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Supernus Pharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady basic indicators, Supernus Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Oric Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Oric Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's forward indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Supernus Pharmaceuticals and Oric Pharmaceuticals

The main advantage of trading using opposite Supernus Pharmaceuticals and Oric Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Supernus Pharmaceuticals position performs unexpectedly, Oric Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oric Pharmaceuticals will offset losses from the drop in Oric Pharmaceuticals' long position.

The idea behind Supernus Pharmaceuticals and Oric Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.